Lit Matters #2: Anticoagulation Trends in PE

Unfractionated heparin remains the dominant initial anticoagulant for acute pulmonary embolism in US hospitals despite guideline support for LMWH and the practical advantages of DOACs. Across 2011 to 2020, UFH use rose while LMWH fell and DOAC adoption climbed from essentially none to a meaningful minority.

PE Anticoagulation Practice Trends

• UFH remains dominant: Initial treatment with unfractionated heparin increased from 41.9% to 56.3% over the decade, making the least predictable option the most common real-world starting choice for acute PE.
• LMWH use declined: Low molecular weight heparin fell from 58.1% to 37.3% even though it offers more stable pharmacokinetics, avoids serial aPTT or anti-Xa titration, and carries less HIT risk than UFH.
• DOAC adoption increased: Direct oral anticoagulants rose from 0% in 2011 to 6.4% in 2020, tracking with FDA approvals and later guideline uptake. We get into why the curve still stayed surprisingly shallow in the episode.
• Therapeutic heparin problem: Only about 22% to 25% of patients on UFH reach therapeutic levels in prior PE studies, a persistent pharmacology gap that helps explain why many clinicians question UFH as a default.
• Outcomes stayed modest: Median hospital stay fell from 4 days to 3 days, while in-hospital mortality held near 2.4%, suggesting major shifts in initial anticoagulant choice did not obviously move these top-line inpatient outcomes.

Who Still Gets UFH

• ICU-level illness signal: ICU admission was the strongest predictor of UFH use, with an adjusted odds ratio of 6.90, reinforcing that clinicians still favor a quickly reversible agent when PE looks sick or unstable.
• Escalation therapy association: Systemic thrombolysis and early vasopressor use were both linked to UFH selection, consistent with a high-risk PE mindset where procedural flexibility often drives the first anticoagulant choice.
• Renal dysfunction effect: Chronic kidney disease and acute renal failure on admission both pushed clinicians toward UFH, a familiar pattern whenever drug clearance and reversibility start to dominate bedside decisions.
• Hospital-type variation: Large teaching hospitals and Northeastern centers were more likely to start UFH, while smaller and rural hospitals leaned away from it, showing that PE anticoagulation remains highly practice-pattern dependent.
• Reversibility misnomer: The idea that LMWH blocks later thrombolysis or catheter-based escalation is overstated, and that practical distinction is worth hearing in the episode.